• 1
    von Euler H., Einarsson R., Olsson U., et al. Serum thymidine kinase activity in dogs with malignant lymphoma A potent marker for prognosis and monitoring the disease. J Vet Intern Med. 2004; 18: 697702.
  • 2
    Hallek M., Wanders L., Strohmeyer S., et al. Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 1992;1:15.
  • 3
    O'Neill KL, Buckwalter MR, Murray BK. Thymidine kinase: Diagnostic and prognostic potential. Expert Rev Mol Diagn 2001;1:428433.
  • 4
    Hannigan BM, Barnett YA, Armstrong DB, et al. Thymidine kinases: The enzymes and their clinical usefulness. Cancer Biother 1993;8:189197.
  • 5
    Niakamura N., Momoi Y., Watari T., et al. Plasma thymidine kinase activity in dogs with lymphoma and leukemia. J Vet Med Sci 1997; 10:957960.
  • 6
    Micke O., Schafer U., Wormann B., et al. Circadian variation of interleukin-2 receptors, serum thymidine kinase and beta-2 microglobulin in patients with non-Hodgkin's lymphoma and normal controls. Anticancer Res 1997;17:30073010.
  • 7
    Bates SE. Clinical applications of serum tumor markers. Ann Int Med 1991;115:623638.
  • 8
    He Q., Zou PA, Lui JX, Skog S., Fornander T. The clinical significance of thymidine kinase I measurement in serum of breast cancer patients using the anti-TK1 antibody. Int J Biol Markers 2000;15:139146.